PEAK3
Protein PEAK3
Also known as: C19orf35, FLJ45778, PEAK3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6ZS72
- Gene
- PEAK3
- Ensembl
- ENSG00000188305
- Chromosome
- 19
- Canonical length
- 473 aa
- Protein class
- Enzymes, Predicted intracellular proteins
- Subcellular location
- Cytosol
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Predicted to enable protein kinase activity. Involved in regulation of actin cytoskeleton organization and regulation of cell shape. Predicted to be active in actin cytoskeleton and focal adhesion. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
473 residues, UniProt reviewed canonical sequence.
>Q6ZS72|PEAK3
1 MSSPEPPTEP PEPDNPTWST QPTYSNLGQI RAHLLPSKAC RLRTPGSLST NPEPLPPPLP
61 KKILTRTQSL PTRRTLHPSS IQVQPPRRPF LGSHSVDKSQ AAVGPACLPA ELTFGPADAP
121 LGLSLRDLHS PEAVHTALAA RQLQGLRTIY ARLRARLMGG HPGPCHPGHS FRLLDSSPCA
181 ESGDALYYRV VRAHEDAWHI LVAKVPKPGA DVPHPWGLEL QASLSPHFNL QGLCGLVPEG
241 TLPGAPWRGA VALAAEVPER TVAQWLAEAC TQPPEEFVWA VALLLLQLSA ALKFLEAWGA
301 ALVELRPENL LLVAPRGCAT TGPPRLLLTD FGRVCLQPPG PPGSPGPHAP QLGSLLRALL
361 SLAAPSTTPL AAGLELLAAQ LTRLRPSASR TRGALQALLW GPGPELRGRG APLGPWLRAL
421 GPWLRVRRGL LVLRLAERAA GGEAPSLEDW LCCEYLAEAT ESSMGQALAL LWDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PEAK3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.39
- Highest tissue expression
- 3.9 nTPM
Expression across tissuesHPA
Tissue
- spleen: 3.9 nTPM
- bone marrow: 2.2 nTPM
- appendix: 1.2 nTPM
- lung: 1 nTPM
- heart muscle: 0.7 nTPM
- small intestine: 0.7 nTPM
Single-cell type
- neutrophils: 50 nCPM
- epicardial cells: 21 nCPM
- neutrophil progenitors: 20 nCPM
- b-cells: 12 nCPM
- medullary thymic epithelial cells: 9.6 nCPM
- mast cells: 8.9 nCPM
Immune cell
- neutrophil: 40 nTPM
- eosinophil: 12 nTPM
- basophil: 10 nTPM
- intermediate monocyte: 5.6 nTPM
- NK-cell: 4.5 nTPM
- classical monocyte: 4.3 nTPM
Brain region
- cerebral cortex: 4.5 nTPM
- medulla oblongata: 4 nTPM
- midbrain: 3.2 nTPM
- pons: 3.2 nTPM
- basal ganglia: 3 nTPM
- spinal cord: 2.9 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.78
- gnomAD pLI
- 0
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
InteractionsUniProt · HPA
Protein binding partners of PEAK3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PEAK3 as an antibody target. Whether an autoantibody or antibody against PEAK3 could matter depends on whether native PEAK3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PEAK3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PEAK3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...